Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

A new study has found that wearable heart monitors can help doctors detect more cases of atrial fibrillation (AFib), a common ...

Withings has announced the Body Scan 2, a new smart scale that the French health tech company says can track over 60 ...